Exicure, Inc.
NasdaqCM · USDExicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Analytick AI is a research platform. Output is informational and not financial advice — trade at your own risk.
Analytick AI is a product of Analytick Inc. · Rockville, Maryland, 20852, United States
© 2026 Analytick AI
Be the first to share your outlook and start the conversation with other investors in the XCUR community.